Silence Therapeutics Statistics Share Statistics Silence Therapeutics has 47.23M
shares outstanding. The number of shares has increased by 202.77%
in one year.
Shares Outstanding 47.23M Shares Change (YoY) 202.77% Shares Change (QoQ) 0.01% Owned by Institutions (%) 15.13% Shares Floating 37.61M Failed to Deliver (FTD) Shares 697 FTD / Avg. Volume 0.6%
Short Selling Information The latest short interest is 923.02K, so 1.95% of the outstanding
shares have been sold short.
Short Interest 923.02K Short % of Shares Out 1.95% Short % of Float 2.47% Short Ratio (days to cover) 8.89
Valuation Ratios The PE ratio is -7.17 and the forward
PE ratio is -12.38.
Silence Therapeutics's PEG ratio is
0.44.
PE Ratio -7.17 Forward PE -12.38 PS Ratio 7.51 Forward PS 12.2 PB Ratio 2.42 P/FCF Ratio -4.79 PEG Ratio 0.44
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Silence Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 11.14,
with a Debt / Equity ratio of 0.
Current Ratio 11.14 Quick Ratio 11.14 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $372.91K Profits Per Employee $-390.59K Employee Count 116 Asset Turnover 0.21 Inventory Turnover n/a
Taxes Income Tax 845K Effective Tax Rate -1.9%
Stock Price Statistics The stock price has increased by -69.11% in the
last 52 weeks. The beta is 1.39, so Silence Therapeutics's
price volatility has been higher than the market average.
Beta 1.39 52-Week Price Change -69.11% 50-Day Moving Average 5.83 200-Day Moving Average 6.45 Relative Strength Index (RSI) 33.32 Average Volume (20 Days) 116,441
Income Statement In the last 12 months, Silence Therapeutics had revenue of 43.26M
and earned -45.31M
in profits. Earnings per share was -0.98.
Revenue 43.26M Gross Profit 31.45M Operating Income -63.32M Net Income -45.31M EBITDA -48.99M EBIT -49.58M Earnings Per Share (EPS) -0.98
Full Income Statement Balance Sheet The company has 121.33M in cash and 117K in
debt, giving a net cash position of 121.21M.
Cash & Cash Equivalents 121.33M Total Debt 117K Net Cash 121.21M Retained Earnings -474.04M Total Assets 185.3M Working Capital 150.53M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -67.64M
and capital expenditures -211K, giving a free cash flow of -67.85M.
Operating Cash Flow -67.64M Capital Expenditures -211K Free Cash Flow -67.85M FCF Per Share -1.44
Full Cash Flow Statement Margins Gross margin is 72.7%, with operating and profit margins of -146.38% and -104.74%.
Gross Margin 72.7% Operating Margin -146.38% Pretax Margin -102.79% Profit Margin -104.74% EBITDA Margin -113.25% EBIT Margin -146.38% FCF Margin -156.85%
